Funding for this research was provided by:
TB REACH (STBP/TBREACH/GSA/W6-5)
Received: 4 January 2019
Accepted: 15 April 2019
First Online: 16 May 2019
Ethics approval and consent to participate
: The trial protocol has obtained ethical approval from the Office of Research Ethics at the University of Toronto (Ref: 36569) on 14 September 2018 and the Ethics Review Committee of the Tibet Centre for Disease Control and Prevention (Ref: 006) on 3 August 2018. Informed consent forms with patients’ preference of language (Tibetan or Chinese) will be collected before any patient is recruited into the study. The TB physician will fully explain the information sheet and consent form to the participant in Tibetan or Chinese. Both the participant and the TB physician are required to sign the consent form. If the participant is not able to sign due to illiteracy, they can use their thumbprint instead. The TB physician will keep the signed informed consent form and leave a copy to the participants for their reference.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.